Specifically, although ERK5 downregulation on its own appeared to accelerate tumor growth (Fig. 7A), the silencing of ERK5 significantly enhanced the antitumor activity of lapatinib, thereby confirming the relevant role of ERK5 signaling in mediating therapeutic resistance to anti-HER2 targeting (Fig. 7B). The gene discussed is ERBB2; the disease is neoplasm.